Phase 3 study of Amigal for the treatment of Fabry disease - MPR

Links shared publicly online about this topic.

1,950
total visits

Phase 3 study of Amigal for the treatment of Fabry disease - MPR

Amicus Therapeutics announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal (migalastat hydrochloride) for the treatment of Fabry disease.

View full resource at empr.com

Tags: Disease and Condition, Drug, Phase 3 Clinical Trial, News, disease

Most Recently Shared on June 22, 2009 at 6:38 pm By:

MPR

MPR News: Phase 3 study of Amigal for the treatment of Fabry disease : Amicus Therapeutics announced it.. http://tinyurl.com/kj7se2

3 years ago...

Retweet

Favorite

GSK and Amicus announce Amigal development and commercialization agreement

news-medical.net — “GlaxoSmithKline PLC (GSK) and Amicus Therapeutics today announced a definitive agreement to develop and commercialize Amigal" (migalastat HCl), currently in Phase 3 for the treatment of Fabry disease, a rare inherited disorder. Under the terms of the agreement, GSK will receive an exclusive worldwide license to develop, manufacture and commercialize migalastat HCl.” View full resource at news-medical.net

Most Recently Shared on October 29, 2010 at 4:27 pm By:

News-Medical.Net Health News

Stroke News: GSK and Amicus announce Amigal development and commercialization agreement: GlaxoSmithKline PLC (GS... http://twurl.nl/mr7ybd

2 years ago...

Retweet

Favorite

Amicus Therapeutics Presents Positive Data Update From Phase 2 Extension Study Of Amigal(TM) For Fabry Disease

medicalnewstoday.com — “Amicus Therapeutics (Nasdaq: FOLD) announced additional positive preliminary data from its ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry dise” View full resource at medicalnewstoday.com